SLUMP

Trump health policy uncertainty sends biotech sector into deeper slump

Mass firings at the U.S. Food and Drug Administration are particularly risky for small- and mid-cap biotech companies that have innovative treatments in clinical trials but no products on the market to keep them afloat, these sources told Reuters.